Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells

Chinese Medical Journal

Volumn 119, Issue 13, 2006, Pages 1088-1093

  Peng, Kan Fu ^a   Wu, Xiong Fei ^a   Zhao, Hong Wen ^a   Sun, Yan ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced oxidation protein products; Atherosclerosis; Mitogen activated protein kinase; Monocyte chemoattractant protein 1; Myocytes; Smooth muscle

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADVANCED OXIDATION PROTEIN PRODUCT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; UREMIC TOXIN;

ANIMAL CELL; ARTERY MUSCLE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; INFLAMMATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

EID: 33746154434     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200607010-00005     Document Type: Article

References (20)

1. Witko-Sarsat V, Fedlander M, Capeiltere-Blandin C, Nguyen-Khao T, Nguyen-AT, Zingraff J,et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
2. Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential toxins? Kidney Int Suppl 2003; (84): s11-s14.
3. Yuan F, Liu SX, Hou FF, Chen Y, Tian JW, Liu ZQ. Advanced oxidation protein products induce oxidative stress in human endothelial cells. Med J Chin People's Liberation Army (Chin) 2004; 11: 951-954.
4. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213-225.
5. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Aced Sci U S A 1991; 88: 5252-5256.
6. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup ST al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
7. US renal data system, USRDS 1998 annual data report. USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. (Accessed September 12, 2003 at http://www.usrds.org/adr1998.htm.)
8. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. Hypertension 1989; 13 (5 Suppl): 180-193.
9. Foley RN, Parfrey PS, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl 3): s112-s119.
10. Foley RN, Parfrey PS, Hamett JD. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031.
11. Descamps-Latscha B, Jungers P, Witko-Sarsat V. Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 2002; 20: 481-484.
12. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative stress: biological aspects clinical consequences and therapy. Semin Dial 2001; 14: 193-199.
13. Witko-Sarsat V, Gausson V, Nguyen AT. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82-91.
14. Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, et al. Advanced oxidation protein products atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 23: 1161-1168.
15. Kalousova M, Zima T, Tesar V. Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif 2002; 20: 531-536.
16. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990; 87: 5134-5138.
17. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al. Lipoprotein in cocultures; of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-2046.
18. Valente AJ, Rozek MM, Sprague EA, Schwartz CJ. Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation 1992; 86: 11120-11125.
19. De Keulenaer GW, Ushio-Fukai M, Yin Q, Chung AB, Lyons PR, Ishizaka N, et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factoralpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 385-391.
20. Goebeler M, Kilian K, Gillitzer R, Kunz M, Yoshimura T, Brocker EB, et al. The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endotheliall cells. Blood 1999; 93: 857-865.